Published in J Acquir Immune Defic Syndr on September 01, 2002
Sex, Aging and Antiretroviral Pharmacokinetics | NCT00666055
Host determinants of HIV-1 control in African Americans. J Infect Dis (2010) 2.90
Youth, unemployment, and male gender predict mortality in AIDS patients started on HAART in Nigeria. AIDS Care (2009) 1.43
Pediatric HIV-1 in Kenya: pattern and correlates of viral load and association with mortality. J Acquir Immune Defic Syndr (2009) 1.14
Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients. J Womens Health (Larchmt) (2013) 1.14
Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load. AIDS (2009) 1.11
The impact of sex, gender and pregnancy on 2009 H1N1 disease. Biol Sex Differ (2010) 1.10
Cumulative impact of host and viral factors on HIV-1 viral-load control during early infection. J Virol (2012) 1.07
Sex differences in neuropsychological performance as an effect of human immunodeficiency virus infection: a pilot study in Zambia, Africa. J Nerv Ment Dis (2012) 1.06
Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. Bioessays (2012) 1.04
Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther (2011) 1.02
Factors associated with CD4 lymphocyte counts in HIV-negative Senegalese individuals. Clin Exp Immunol (2008) 1.00
Depo-Provera abrogates attenuated lentivirus-induced protection in male rhesus macaques challenged intravenously with pathogenic SIVmac239. J Med Primatol (2007) 0.98
Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001. J Epidemiol Community Health (2004) 0.96
X chromosomal variation is associated with slow progression to AIDS in HIV-1-infected women. Am J Hum Genet (2009) 0.92
Viral and host factors associated with the HIV-1 viral load setpoint in adults from Mbeya Region, Tanzania. J Acquir Immune Defic Syndr (2010) 0.89
Time for gender mainstreaming in editorial policies. J Int AIDS Soc (2011) 0.89
Increased circulating interleukin-7 levels in HIV-1-infected women. J Acquir Immune Defic Syndr (2005) 0.87
Cell-mediated immunity to HIV in the female reproductive tract. J Reprod Immunol (2009) 0.87
Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review. AIDS Res Hum Retroviruses (2015) 0.86
Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: a multisite cohort study. PLoS One (2013) 0.86
HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077. PLoS One (2014) 0.84
HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection. J Clin Microbiol (2009) 0.82
Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies. Clin Infect Dis (2009) 0.82
Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy. Clin Infect Dis (2013) 0.79
CCR5 expression is reduced in lymph nodes of HIV type 1-infected women, compared with men, but does not mediate sex-based differences in viral loads. J Infect Dis (2013) 0.78
Sex Differences in HIV: Natural History, Pharmacokinetics, and Drug Toxicity. Curr Infect Dis Rep (2005) 0.77
Absence of effect of menopause status at initiation of first-line antiretroviral therapy on immunologic or virologic responses: a cohort study from Rio de Janeiro, Brazil. PLoS One (2014) 0.77
Gender differences in oral lesions among persons with HIV disease in Southern India. J Oral Maxillofac Pathol (2012) 0.76
Sex disparities in outcomes among adults on long-term antiretroviral treatment in northern Nigeria. Int Health (2016) 0.75
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Neighborhood characteristics associated with the location of food stores and food service places. Am J Prev Med (2002) 13.39
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med (2007) 10.43
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med (2007) 7.87
Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60
Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology (2007) 5.77
Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS (2008) 4.21
Preventable drug-related hospital admissions. Ann Pharmacother (2002) 3.78
A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Illustrating bias due to conditioning on a collider. Int J Epidemiol (2009) 3.54
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol (2010) 3.45
The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis (2009) 3.44
Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med (2003) 3.32
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
The ongoing tyranny of statistical significance testing in biomedical research. Eur J Epidemiol (2010) 3.10
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA (2002) 2.94
Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol (2004) 2.91
Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.91
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses (2002) 2.89
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Living with p values: resurrecting a Bayesian perspective on frequentist statistics. Epidemiology (2013) 2.86
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
A code of ethics for public health. Am J Public Health (2002) 2.48
Frequent detection of acute primary HIV infection in men in Malawi. AIDS (2004) 2.43
Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics (2003) 2.38
Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest (2004) 2.30
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS (2008) 2.25
Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord (2007) 2.24
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS (2011) 2.22
Late entry to HIV care among Latinos compared with non-Latinos in a southeastern US cohort. Clin Infect Dis (2011) 2.20
Moving forward in HIV-associated cancer. J Clin Oncol (2014) 2.14
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.02
Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr (2006) 2.01
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS (2003) 1.99
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96
Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. Arch Intern Med (2003) 1.96
Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis (2011) 1.91
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol (2007) 1.86
Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care (2006) 1.76
Perinatal exposure to hazardous air pollutants and autism spectrum disorders at age 8. Epidemiology (2010) 1.75
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med (2014) 1.75
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS (2004) 1.74
A time-series analysis of air pollution and preterm birth in Pennsylvania, 1997-2001. Environ Health Perspect (2005) 1.70
Splines for trend analysis and continuous confounder control. Epidemiology (2011) 1.69
Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis (2011) 1.68
A systematic review and meta-regression of temporal trends in adult CD4(+) cell count at presentation to HIV care, 1992-2011. Clin Infect Dis (2013) 1.67
Bounding causal effects under uncontrolled confounding using counterfactuals. Epidemiology (2005) 1.67
Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. Am J Epidemiol (2009) 1.63
Epidemiologic measures of the course and outcome of pregnancy. Epidemiol Rev (2002) 1.62
IGF-I and IGFBP-3 polymorphisms in relation to circulating levels among African American and Caucasian women. Cancer Epidemiol Biomarkers Prev (2009) 1.58
Late diagnosis of HIV in young men in North Carolina. Sex Transm Dis (2007) 1.58
Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. AIDS Res Hum Retroviruses (2010) 1.58
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. J Immunol (2012) 1.57
Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J Infect Dis (2013) 1.55
Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr (2005) 1.52
Improved estimation of controlled direct effects in the presence of unmeasured confounding of intermediate variables. Stat Med (2005) 1.51
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis (2003) 1.51
Nonexperimental comparative effectiveness research using linked healthcare databases. Epidemiology (2011) 1.50
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr (2004) 1.48
"Toward a clearer definition of confounding" revisited with directed acyclic graphs. Am J Epidemiol (2012) 1.48
HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial. Ann Intern Med (2015) 1.47
No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis (2010) 1.45
Estimating personal exposures from ambient air pollution measures: using meta-analysis to assess measurement error. Epidemiology (2014) 1.45
Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis (2011) 1.45
Frequent detection of acute HIV infection in pregnant women. AIDS (2007) 1.43
Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int (2005) 1.40
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr (2006) 1.40
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 1.39
Experimental demonstration of continuous electronic structure tuning via strain in atomically thin MoS2. Nano Lett (2013) 1.38
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS (2012) 1.38
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis (2006) 1.37
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol (2004) 1.37
Utility of International Classification of Diseases, Ninth Revision, Clinical Modification codes for communicable disease surveillance. Am J Epidemiol (2010) 1.36
Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother (2012) 1.36
Conditions for bias from differential left truncation. Am J Epidemiol (2006) 1.35
Causal inference from randomized trials in social epidemiology. Soc Sci Med (2003) 1.35
Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. AIDS (2007) 1.33
Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One (2011) 1.32
Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis (2013) 1.31
APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology (2004) 1.30
Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors. AIDS (2006) 1.30
Association of multiple anthropometrics of overweight and obesity with incident heart failure: the Atherosclerosis Risk in Communities study. Circ Heart Fail (2009) 1.30